Center for Neuro-Oncology, Department of Medical Oncology, Dana-Farber/Brigham and Women's Cancer Center, SW430D, 44 Binney Street, Boston, MA 02115, USA.
Curr Oncol Rep. 2011 Feb;13(1):50-6. doi: 10.1007/s11912-010-0143-y.
Accuracy and reproducibility in determining response to therapy and tumor progression can be difficult to achieve for nervous system tumors. Current response criteria vary depending on the pathology and have several limitations. Until recently, the most widely used criteria for gliomas were "Macdonald criteria," based on two-dimensional tumor measurements on neuroimaging studies. However, the Response Assessment in Neuro-Oncology (RANO) Working Group has published new recommendations in high-grade gliomas and is working on recommendations for other nervous system tumors. This article reviews current response criteria for high-grade glioma, low-grade glioma, brain metastasis, meningioma, and schwannoma.
确定神经系统肿瘤对治疗的反应和肿瘤进展的准确性和可重复性可能具有挑战性。目前的反应标准取决于病理学,并且具有几个局限性。直到最近,最广泛用于脑肿瘤的标准是“Macdonald 标准”,该标准基于神经影像学研究中的二维肿瘤测量。然而,神经肿瘤学反应评估 (RANO) 工作组已经发表了高级别胶质瘤的新建议,并正在为其他神经系统肿瘤制定建议。本文综述了高级别胶质瘤、低级别胶质瘤、脑转移瘤、脑膜瘤和 schwannoma 的现行反应标准。